February is Rare Disease Month and a great time to consider whether your loved one is eligible to participate in a Fragile X syndrome clinical research program.
The EXPERIENCE clinical studies, Shionogi’s ongoing Phase 2b/3 studies for an investigational drug for Fragile X syndrome, are still enrolling qualified male participants aged 9-45 with FXS and confirmed FMR1 gene mutation (≥ 200 CGG repetitions) at sites across the U.S.
You may have heard about EXPERIENCE (Evaluation of Fragile X Experience in Cognition Expression) clinical trials as the Tetra studies or the studies of BPN14770 in Fragile X syndrome. The EXPERIENCE clinical studies are now being managed by Shionogi (the company that acquired Tetra Therapeutics Inc. in 2020).
Travel to and from sites for a study participant and his caregiver may be covered, and may also include transportation, lodging arrangements, and reimbursement for meals (limitations may apply).
Find out about EXPERIENCE at www.shionogi.com/FXS. You can also contact Shionogi directly at medinfo@shionogi.com or 1-800-849-9707.
